Core Partnership Areas

Retrospective Analysis

Sponsor Imaging and Clinical Data from completed studies, processed by Brainomix to provide insights, or to train and develop specific
AI-biomarkers.

Prospective Trials

Sponsor Imaging and Clinical Data from on-going studies, processed by Brainomix to provide insights, or to train and develop specific
AI-biomarkers.

Real-World Data

Real World Data and Evidence utilised to provide clinical insights for sponsors on trial design, presenting population and statistical support for endpoint power calculations.

Bespoke Development

Creation and validation of novel digital biomarkers and bespoke software for Life Science partners.

Driving Treatment Decisions

Adoption of digital biomarkers into clinical decision pathways for improved disease diagnosis and the acceleration of therapeutic treatment decisions.

Service Offering

Work with Brainomix today to support your clinical development.

Extensive AI-imaging expertise and experience across multi-center clinical trials
Proprietary biomarkers, bespoke digital biomarkers and software development services
Comprehensive AI-powered Core Lab analytics with AI-enhanced Central Reads
Automated and customizable patient selection software to prospectively identify and enrich study cohorts
Expert radiology review of imaging data for eligibility adherence, safety assessment and longitudinal clinical insights
Expert medical and imaging consultants for clinical support on trial design, execution, and interpretation

Life Science Partners

Brainomix's services support a wide array of Life Science companies from across the globe, including biotech start-ups, large pharma partners, and medical device companies. Here are some of our partners:

CSL Research Collaboration

A recent publication in Frontiers in Neurology, stemming from an international research collaboration with CSL, validated the significance of Brainomix's follow-up infarct volume (FIV) automated imaging biomarkers to predict clinical outcomes after acute ischemic stroke (AIS).

"CSL is proud to champion research which can improve and optimize clinical trial design. Working with partners like Brainomix, we are contributing to a better understanding of selection and endpoint markers in acute ischemic stroke, which in turn can improve the development of treatment for patients," Moshe Vardi, MD, Vice President, R&D Therapeutics Area Co-Lead at CSL.

"Brainomix has the most extensive and well validated suite of AI biomarkers in the field of stroke. It was a pleasure to collaborate on this important research, showing how Brainomix's quantitative AI imaging can improve patient characterization and outcome assessment in stroke clinical trials," Dr Waleed Brinjikji, Professor of Radiology & Neurosurgery, Mayo Clinic.

Brainomix Biomarkers Powering TIPAL Study

"We are excited to include Brainomix AI biomarkers in our TIPAL study. Brainomix technology has shown it can provide robust quantification of changes in fibrosis and disease status during ILD treatment, which will add greater data insights into our study," Prof Andrew Wilson, Chief Investigator, Clinical Professor, Norfolk and Norwich University Hospitals.

TIPAL is a multicenter clinical trial designed to find out if proton pump inhibitors (anti-acid drugs) are beneficial for people with idiopathic pulmonary fibrosis (IPF).

"The use of Brainomix's comprehensive suite of e-Lung biomarkers will unlock novel mechanistic insights into the potential utility of Lansoprazole in idiopathic pulmonary fibrosis. This collaboration on an NIHR-funded study reiterates Brainomix's commitment to research and to advancing the field for IPF patients across the globe," Dr Peter George, Brainomix Senior Medical Director.

Brainomix and AstraZeneca partnered to analyze Phase 2 tralokinumab clinical trial data, leveraging Brainomix’s AI-powered software and biomarkers to uncover novel insights. The output of this partnership has been published in the AJRCCM.

“As key components in AstraZeneca’s strategy to bring new medicines to patients faster and more effectively, data science and AI are transforming R&D. Our collaboration with Brainomix helped us to expand our understanding of the potential that innovative AI approaches can bring to improving the design of clinical trial for patients with Interstitial Lung Disease.”

Dr. Kristoffer Ostridge Head of Experimental Medicine, AstraZeneca

Brainomix and Bridge Biotherapeutics, Inc. have partnered on the BBT-877 (NCT05483907) study which is assessing treatment effect in IPF. Brainomix technology and AI imaging biomarkers have been selected to provide deep data analytics which will enrich the clinical development of BBT-877.

“We believe that the partnership with Brainomix will enable us to generate supplemental efficacy data from our clinical study on IPF patients based on their combined imaging technology and expertise. We expect to gain further insights with regard to earlier prediction of treatment response in patients, as the partnership goes on.”

Agnes Jung Head of Project Management at Bridge Biotherapeutics Inc

Brainomix and Argenica Therapeutics have partnered on the ARG-007-002 study (ACTRN12623001110673). Brainomix AI expertise and analytics are supporting the clinical development of ARG-007 through robust characterization of treatment effect and identification of responsive phenotypes.

“Brainomix expertise and AI-enhanced imaging allows to do more with our clinical trial data, giving us a better indication of treatment effect and allowing us to dig into key biomarkers.”

Liz Dallimore CEO Argenica Therapeutics

"Clario’s extensive experience in clinical trials combined with Brainomix’s portfolio of advanced analytics creates a powerful and efficient integrated solution for stroke therapies in clinical development. Together with Brainomix we have successfully designed and delivered a number of next-generation AI-enhanced studies and look forward to continued collaboration in this space."

Dr Meredith Burke, PhD VP, Medical Imaging

Contact Our Team

Ross Stewart

Associate Director, Life Sciences

Contact

“I have been proud to contribute to our Life Science Partnerships during my time at Brainomix. Our approach is critically focused on delivering sustainable, mutually aligned value to our Partners, and I am confident in our capabilities to work within this ecosystem to make a positive impact on patient outcomes.”

Ross has significant experience in Life Science Partnerships, specifically focused on imaging biomarker development and quantitative analysis to support therapeutic research with AI-based imaging.

With particular interest in imaging driven clinical programmes, Ross has been actively involved in the development, execution, and management of more than 40 partnerships and clinical trials with Pharma sponsors.

During 10+ years of experience, Ross has worked with a full range of different size Life Science organizations, including Pharma, Biotech, and Device Manufacturers, along with significant experience in working in partnership with many full-service and imaging CROs.